Amedisys (NASDAQ:AMED – Get Rating) had its price objective decreased by SVB Leerink from $117.00 to $107.00 in a report released on Tuesday, Stock Target Advisor reports. SVB Leerink currently has a market perform rating on the health services provider’s stock. SVB Leerink also issued estimates for Amedisys’ Q1 2023 earnings at $1.43 EPS, Q2 2023 earnings at $1.58 EPS, Q3 2023 earnings at $1.45 EPS, Q4 2023 earnings at $1.48 EPS, FY2023 earnings at $5.94 EPS, FY2024 earnings at $6.27 EPS, FY2025 earnings at $6.45 EPS and FY2026 earnings at $7.34 EPS.
A number of other brokerages also recently issued reports on AMED. UBS Group upgraded Amedisys from a sell rating to a neutral rating and raised their price objective for the stock from $152.00 to $168.00 in a research report on Tuesday, March 1st. Royal Bank of Canada lowered their price objective on Amedisys from $221.00 to $199.00 and set an outperform rating for the company in a research report on Friday, February 25th. Credit Suisse Group lowered their price objective on Amedisys from $200.00 to $195.00 and set an outperform rating for the company in a research report on Friday, February 25th. Bank of America downgraded Amedisys from a neutral rating to an underperform rating and lowered their price objective for the stock from $145.00 to $102.00 in a research report on Tuesday. Finally, Benchmark lowered their price objective on Amedisys from $200.00 to $175.00 and set a buy rating for the company in a research report on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $173.27.
Shares of AMED stock opened at $115.28 on Tuesday. The business’s 50-day moving average price is $122.52 and its 200-day moving average price is $142.33. Amedisys has a 12 month low of $101.61 and a 12 month high of $276.21. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 2.10 and a beta of 0.89. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42.
In related news, insider David L. Kemmerly sold 2,500 shares of Amedisys stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the transaction, the insider now owns 16,336 shares of the company’s stock, valued at $2,896,536.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.10% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. Covestor Ltd purchased a new position in shares of Amedisys during the fourth quarter valued at approximately $28,000. Harel Insurance Investments & Financial Services Ltd. boosted its position in Amedisys by 55.3% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock worth $38,000 after purchasing an additional 83 shares during the last quarter. Allworth Financial LP purchased a new position in Amedisys in the first quarter worth $38,000. Confluence Wealth Services Inc. purchased a new position in Amedisys in the fourth quarter worth $42,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in Amedisys in the first quarter worth $46,000. 90.47% of the stock is currently owned by institutional investors.
Amedisys Company Profile (Get Rating)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.